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INTRODUCTION
The number of medicines that patients 
take is increasing.1 This is driven by a 
complex mix of an ageing population,2 an 
increase in multimorbidity,2–4 an increasing 
tendency to prescribe preventive medicines 
to asymptomatic patients,5 and applying 
multiple single-disease guidelines to 
patients with multimorbidy.3 Drug-related 
problems, such as adverse drug reactions, 
high-risk prescribing, medicine errors, and 
poor adherence, increase with the number 
of medicines prescribed6–9 and result in 
6.5% of all hospital admissions.10,11 
Polypharmacy is not always harmful, 
however, and Duerden et al make 
the distinction between appropriate 
polypharmacy, such as where multiple 
medicines improve quality of life, prolong 
life, and cause minimal harm, and 
problematic polypharmacy, where the 
balance tips and the potential harm of some 
medicines outweighs the potential benefit.3 
Frail older patients with multimorbidity are 
most at risk of problematic polypharmacy 
because they benefit less from strict control 
of risk factors and are more at risk of 
the side effects of certain medicines.12 
Treatment burden (the effort of looking after 
one’s health) should also be considered.13 
Taking lots of medicines at different times 
of the day is challenging for many patients, 
particularly people with frailty, impaired 
cognition, or reduced dexterity.14
One opportunity to reduce problematic 
polypharmacy is to conduct a regular 
medication review, defined by the National 
Institute for Health and Care Excellence 
(NICE) as ‘a structured, critical examination 
of a person’s medicines with the objective 
of reaching an agreement with the person 
about treatment, optimising the impact 
of medicines, minimising the number of 
medicine-related problems and reducing 
waste’.15 Though others may also benefit, 
NICE recommends that patients who are 
frail and those with multimorbidity and/
or polypharmacy should be prioritised for 
medication review.15 The STOPP/START 
guideline offers some guidance on stopping 
or tapering down medicines for frail older 
patients.16
Reflecting rising GP workloads and 
problems consequent of low GP recruitment 
and retention,17 there are initiatives across the 
UK to increase the number of practice-based 
pharmacists (PBPs).18 These pharmacists 
are employed by the GP surgery and carry 
out non-dispensing roles, such as reconciling 
medicines following hospital discharge 
and reviewing prescription requests from 
patients and community pharmacists. Some 
PBPs have a role in patient-facing activities 
that include medication review. Relatively 
little is known about how official guidelines 
for medication review are being enacted 
within routine practice. The aim of this study 
was to explore how GPs and pharmacists 
carry out medication reviews in general 
practice in the UK. 
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Abstract
Background
Medication reviews may improve the safety of 
prescribing and the National Institute for Health 
and Care Excellence (NICE) highlights the 
importance of involving patients in this process. 
Aim
To explore GP and pharmacist perspectives 
on how medication reviews were conducted in 
general practice in the UK. 
Design and setting
Analysis of semi-structured interviews with GPs 
and pharmacists working in the South West 
of England, Northern England, and Scotland, 
sampled for heterogeneity. Interviews took place 
between January and October 2017.
Method
Interviews focused on experience of medication 
review. Data saturation was achieved when 
no new insights arose from later interviews. 
Interviews were analysed thematically.
Results
In total, 13 GPs and 10 pharmacists were 
interviewed. GPs and pharmacists perceived 
medication review as an opportunity to improve 
prescribing safety. Although interviewees thought 
patients should be involved in decisions about 
their medicines, high workload pressures meant 
that most medication reviews were conducted 
with limited or no patient input. For some GPs, a 
medication review was done ‘in the quickest way 
possible to say that it was done’. Pharmacists 
were perceived by both professions as being more 
thorough but less time efficient than GPs, and few 
pharmacists were routinely involved in medication 
reviews even in practices employing a pharmacist. 
Interviewees argued that it was easier to continue 
medicines than it was to stop them, particularly 
because stopping medicines required involving the 
patient and this generated extra work. 
Conclusion
Practices tended to prioritise being efficient 
(getting the work done) rather than being 
thorough (doing it well), so that most medication 
reviews were carried out with little or no patient 
involvement, and medicines were rarely stopped 
or reduced. Time and resource constraints are 
an important barrier to implementing NICE 
guidance.
Keywords
care of older people; medication review; 
polypharmacy; primary health care; qualitative 
research.
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METHOD
Setting, design, and participants
The researchers conducted semi-
structured interviews with GPs and 
pharmacists. Interviewees were recruited 
from practices enrolled in the 3D Study, a 
multicentre, cluster-randomised controlled 
trial of an organisational intervention for 
people with multimorbidity.19 As part of the 
3D intervention, a pharmacist conducted 
a remote medication review and made 
recommendations to the GP to discuss it 
with the patient. In this article the authors 
focus on GP and pharmacist perspectives 
on usual practice of medication review, 
outside the context of the 3D intervention. 
Interviewees were purposively sampled to 
include pharmacists and GPs with a range 
of different experiences and working in 
different contexts. They were recruited from 
practices who had delivered the 3D Study 
intervention and from those in the usual-
care arm of the study. The authors included 
community, practice-based, and clinical 
commissioning group (CCG) pharmacists 
and GPs from practices that did and did 
not employ a practice pharmacist. GPs 
and pharmacists working in different 
geographical regions including the South 
West of England, Northern England, and 
Scotland were also sampled. The authors 
stopped recruiting once data saturation had 
been reached and no new insights arose 
from later interviews. 
Research team and data collection
The research team comprised academic 
GPs, a qualitative researcher, and a 
primary care researcher. All interviews 
were audiorecorded and carried out by a 
research team GP between January 2017 
and October 2017 either face-to-face in 
GP surgeries or over the phone. Interviews 
were based on topic guides developed by 
GPs from the research team tailored for 
either GPs or pharmacists (the common 
topic guide for introduction and background 
for GPs and pharmacists is available from 
the authors on request, Box 1 shows 
the topic guide for GPs, and Box 2 for 
pharmacists). GPs were asked to choose 
a patient with polypharmacy (‘a case 
study’ patient) who was not enrolled in the 
3D Study and, referring to their medical 
records, to talk through how they would 
review their medicines. Practice-based 
pharmacists were asked to give examples 
of medication reviews they had done within 
general practice. The eight pharmacists 
who delivered the 3D Study intervention 
were asked to talk through how they carried 
out a medication review for a number of 
case study patients enrolled in the study. 
The interviews lasted 40–60 minutes — the 
first half of the interview focused on usual 
practice and the second half focused on 
the 3D intervention (article currently being 
written and to be submitted for publication).
Analysis
The audiorecordings were transcribed and 
anonymised. The transcripts were imported 
How this fits in
The National Institute for Health and Care 
Excellence recommends that patients with 
frailty, multimorbidity, and polypharmacy 
should undergo regular medication 
review, and emphasises the importance 
of involving them in this process. This 
study suggests that, although GPs and 
pharmacists recognise the importance 
of involving patients in decisions about 
their medicines, they perceive a trade-
off between involving the patient in 
medication review and being time efficient. 
Professionals may take a pragmatic 
approach to medication review to prioritise 
patients at highest risk, with lack of 
patient involvement a significant barrier to 
stopping medicines.
Box 1. GP interview topic guide
Topic Questions
Usual practice  •  Before we get into the specifics, I’m interested in understanding how 
repeat medications are reviewed in your practice. (How often, within/
outside of consultations, patient involvement, purpose, barriers, 
facilitators?)
 •  Can you tell me about your experience of reviewing medications for 
patients with polypharmacy? (Different from other medication reviews?)
 •  Do pharmacists play a role in medication reviews in your practice? (CCG 
pharmacist or practice pharmacist?)
 •  Are any other non-GP staff involved in medication reviews in your practice?
Usual practice case • Can you think of any non-3D patients who are prescribed lots of  
patients   medications, whom you could look up on EMIS?
 •  Could you talk through how you might review their medications? (Is that 
typical?)
3D Study •  I’d like to ask you to focus more on the 3D Study now. How have you found 
reviewing patients’ medications during the 3D consultations? (Purpose of 
the reviews; pharmacist recommendations, patient involvement, types of 
changes made, examples.)
3D Study case patients • Can you have a read over the record for this patient and talk me  
(2–3 for each interview)   through how you might have come to the decisions about their 
medications? (Changes made; pharmacist recommendations — looked 
at, useful, acted on, concerns; patient involvement; typical of other reviews; 
same as/different from usual practice.)
Any other issues • Any other issues you would like to raise?
3D Study = a multicentre, cluster-randomised controlled trial of an organisational intervention for people with 
multimorbidity.19 CCG = clinical commissioning group EMIS = Egton Medical Information Systems.
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into NVivo (version 11) for analysis. Field 
notes taken immediately after the interviews 
were reviewed to aid interpretation of the 
meaning behind participant responses. The 
interviews were analysed thematically.20 
A GP researcher read and coded all the 
transcripts. Another GP researcher, a 
qualitative researcher, and a primary care 
researcher from the study team read and 
coded a subset of transcripts independently. 
Emerging themes were discussed and a 
coding structure was developed over several 
team meetings between the authors. The 
remaining interviews were coded using 
the agreed framework. As data analysis 
continued, the authors modified the coding 
framework. Mind maps were used to group 
codes under overarching themes.
RESULTS
In total, 10 pharmacists and 13 GPs were 
interviewed about the usual practice of 
medicine review, Table 1 shows the 
participant characteristics. Three main 
themes were identified: organisation of 
medication reviews and repeat prescribing, 
the purpose of medication reviews, and 
patient-centredness.
The organisation of medication reviews 
and repeat prescribing
Though most medication reviews 
undertaken in participating practices were 
completed by GPs, medication review 
involved many individuals across the primary 
care team. Pharmacists were perceived as 
being less time efficient than the GPs and, 
of the six practice-based pharmacists, only 
one was routinely involved in medication 
review.
The role of others in medication reviews. 
Prescription requests in participating 
surgeries were triaged by administrative 
prescription clerks, who performed a 
number of checks and flagged up when 
a medication review was due to the GP. 
Requests that passed the checks were sent 
to the GPs in a separate folder for electronic 
signing. For requests where the medication 
review was out of date, GPs could then 
either ignore this and sign the prescription, 
carry out a remote medication review using 
the patient’s notes, or arrange a medication 
review appointment over the phone, face-
to-face, or in the patient’s home:
‘We do rely on the prescription ladies … 
when we get prescription requests in from 
the patients the prescription ladies will 
funnel that into two streams. One is a 
everything’s up to date, you don’t have 
to think about this kind of ones … then it 
comes through on another pile and you’re 
kind of alert to the fact that there’s the 
query.’ (GP7, female [F]) 
GPs in half of the practices reported that 
more experienced nurses, particularly nurse 
prescribers, carried out some medication 
reviews, usually for more straightforward 
patients who had been prescribed a small 
number of medicines for a small number of 
long-term conditions (for example, patients 
only prescribed asthma medicines who had 
had a nurse-led asthma review):
‘… both nurse prescribers … so they’re both 
quite experienced and we felt that for stable 
people with chronic diseases, which the 
nurses are better than GPs at managing 
anyway, it [medication review] was an 
appropriate thing for them to do by virtue 
of the fact that GPs can’t do everything.’ 
(GP10, male [M])
Only one of the six practice-based 
pharmacists was routinely involved in 
medication review. Both professions 
perceived pharmacists to be more thorough 
in reviewing medications, with GPs often 
Box 2. Pharmacist interview topic guide
Topic Questions
Usual practice  •  Before we get into the specifics, I want to find out a bit more about your 
role as a pharmacist outside of the 3D Study. In particular, whether you are 
involved in medication reviews for patients? (Driven by cost or CCG targets 
or led by the practice? Face-to-face or computer led? Useful or not? 
Barriers, facilitators.) 
 •  Can you tell me about the last time you were involved in medication 
reviews for a practice? (Typical?) 
 • How have you found working with practices?
 •  Have you been involved in medication reviews for patients with 
polypharmacy? (Driven by cost or CCG targets or led by the practice? 
Face-to-face or computer led? Useful or not? Barriers, facilitators.)
3D Study case patients • Before we go on to talk about the case study patients, can you  
(2–3 for each interview)   tell me any thoughts you have about the medication reviews for the 
3D Study? (Working with practices, doing the reviews, purpose, useful.)
 •  Can you have a read over the record for this patient and talk me through 
the process you might have gone through when you reviewed this patient’s 
medications?
 •  Recommendations (types of medicines stopped/started, purpose of 
stopping/starting them, for example, safety, pill burden, guidelines).
 • Typical of other 3D reviews?
 • Same as/different from usual practice?
 •  Reflect on whether the GP acted on the recommendations (typical?).
Any other issues • Any other issues you would like to raise?
3D Study = a multicentre, cluster-randomised controlled trial of an organisational intervention for people with 
multimorbidity.19 CCG = clinical commissioning group. EMIS = Egton Medical Information Systems.
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completing these during consultations for 
other problems or while signing repeat 
prescriptions: 
‘… they [pharmacists] would probably ask 
whether they ever missed the tablets, are 
delayed in taking them, are, um, have you 
taken them having any side effects, if they 
understand what reasons they’re taking all 
the tablets for, probably do a better job than 
me … the reality is that most people when 
they come in have got three other things 
that they want to talk about.’ (GP4, M)
However, GPs were perceived by both 
GPs and pharmacists to be more time 
efficient, with a belief that pharmacists 
required protected time to carry out a face-
to-face medication review focused just on 
medicines, which was hard to organise 
given the other work the pharmacists were 
expected to do:
‘I’m meant to be doing med reviews for 
the nursing homes but, um, I just run 
out of time … it’s just not feasible so I’ve 
been trying to do what I can but it’s time.’ 
(Pharmacist [P]2, F)
Use of electronic prescribing systems. 
Many GPs and pharmacists found the 
use of electronic as opposed to paper 
prescriptions helpful for completing a 
medication review, particularly in terms 
of flagging up interactions and having 
‘information at your fingertips’:
‘I pay a lot more attention when I’m doing it 
electronically … we’d get whole bundles of 
them and there’s no time to do anything but 
just sign them really. But actually if I’ve got 
it electronically, I do tend to often go into the 
patients’ records more ‘cos it’s … it’s easier 
to do so.’ (GP6, F)
However, some found the system clunky 
and found it difficult to communicate with 
patients via the electronic prescribing 
system:
‘… the big problem with electronic 
prescribing is that there is no way … of 
communicating a message to a patient 
anymore.’ (GP4, M)
Case finding. GPs and pharmacists 
discussed the merits of identifying older 
patients with polypharmacy for medication 
reviews but only two practices routinely 
searched for these patients:
‘I’m specifically trying to look at elderly 
patients on 10, 15 medicines, or more, 
getting patients to come in and sit down 
with me for 20 to 30 minute appointment, 
going through their medicines.’ (P6, F)
The purpose of medication reviews
Interviewees reported that the purpose 
of medication reviews included stopping 
or reducing the dose of medicines 
(deprescribing), but they acknowledged 
that this required patient involvement and 
Table 1. Participant characteristics
Characteristic  n
Pharmacists (N = 10)
 Sex  
 Male  3
 Female  7
 Estimated age, years
 31–40  6
 41–50  4
 Time as qualified pharmacist, years
 5–9  4
 10–15  3
 >15  3
 Time working in primary care (for practice-based pharmacists only, N = 6), years
 <2  3
 2–10  0
 >10  3
 Job role  
 Community pharmacist 1
 CCG pharmacist  3
 Practice-based pharmacist 6
 Intervention or usual-care practice
 Delivered the 3D Study intervention 8
 Working in usual-care practice 2
GPs (N = 13)
 Sex
 Male  5
 Female  8
 Estimated age, years  
 31–40  6
 41–50  2
 51–60  5
 Time as qualified GP, years
 <5  3
 5–9  4
 10–15  3
 >15  3
 Job role
 GP partner  10
 Salaried GP  3
 Intervention or usual-care practice 
 Intervention practice 9
 Usual care  4
3D Study = a multicentre, cluster-randomised controlled trial of an organisational intervention for people with 
multimorbidity.19 CCG = clinical commissioning group.
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generated work, and that it was easier 
to continue medicines than to stop them. 
Pharmacists described always checking for 
interactions and monitoring blood tests but 
this was not always done by GPs.
Reducing and stopping inappropriate 
medicines. As part of a medication review, 
interviewees described stopping or tapering 
down medicines that were no longer 
indicated, were potentially causing more 
harm than good, or were resulting in pill 
burden for patients and carers:
‘… people being on ferrous sulphate or 
vitamin D … actually when they were 
re-measured it was now not needed … 
There’s a lot of elderly who seem to have 
been on amitriptyline … combine that with 
other meds that might only have a small 
anticholinergic score and it can soon add 
up.’ (P1, F)
Interviewees felt it was not necessary to 
treat frailer older patients as aggressively 
for some of their long-term conditions, 
citing guidelines that provided different 
treatment targets for these patients:
‘… well I think actually when you’re elderly 
and frail there’s a lot of other considerations 
… so somebody’s cognition, somebody’s 
concordance, somebody’s ability, and in fact 
the appropriateness of a lot of medicines 
can change rapidly … that’s when it’s more 
important to actually check whether they’re 
happy to take these medicines, … whether 
we’re doing more harm than good.’ (GP13, F) 
For many interviewees the key perceived 
barriers to stopping medicines included: 
fear of causing problems; not wanting to 
stop medicines that had been started by 
hospital specialists; and a lack of clear 
evidence and guidelines around stopping 
medicines. Interviewees felt that patients 
might be reluctant or have no incentive to 
stop medicines, particularly those that they 
had taken for a long time and medicines for 
long-term pain:
‘I think we’re all rather allergic to stopping 
things … To take the time to talk all this 
through and to persuade a patient to come 
off would be quite difficult.’ (GP1, F)
There was also a concern that stopping 
medicines generated more work and hassle 
for health professionals, the surgery, and 
patients:
‘… it’s easier to just keep things on the 
medication list than really dig into it and 
stop things.’ (P9, M)
Many of the pharmacists and a few 
GPs had experience of using the STOPP/
START guidelines16 when reviewing a 
patient’s medicines. Though STOPP was 
perceived to provide some rationale for 
stopping medicines, some participants felt 
that guidance on stopping medicines was 
usually less clear than guidance on starting 
medicines:
‘… you get a Q-risk of over whatever then 
you start a statin … it’s not as practical — 
the advice for de-prescribing.’ (P9, M) 
Checking blood tests and for drug–drug 
interactions. Pharmacists felt that 
checking whether the monitoring blood 
tests were up to date, with a view to altering 
drug doses accordingly, and checking for 
drug–drug interactions was an important 
part of the medication review process. GPs 
reported giving less attention to this:
‘… so because of his age I’d probably do a 
creatinine clearance … especially elderly 
patients … I mean I think that’s probably me 
being more cautious.’ (P1, F) 
‘No, I would never try and calculate that 
[the creatinine clearance] … so when 
I first started people on NOACs [novel 
oral anticoagulants] I got quite obsessed 
by looking at their eGFRs [estimated 
glomerular filtration rate] and I would do 
them really regularly but I got rather lax.’ 
(GP1, F) 
Patient-centredness
GPs and pharmacists talked about the 
importance of involving patients in decisions 
about their medicines but said that most 
medication reviews were conducted outside 
of the consultation or hastily alongside 
several other problems being discussed. 
They argued that it was difficult to stop 
medicines without involving the patient.
Involving patients versus being time 
efficient. Interviewees tended to make the 
distinction between ‘simple reviews’, for 
example, younger patients prescribed a 
small number of medicines, and ‘complex 
reviews’, for example, frail older patients 
with multimorbidity and polypharmacy. 
More patient-centred medication reviews 
carried out in dedicated appointments were 
prioritised for more complex patients:
‘If they’re more elderly and we’re concerned 
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about whether they’re taking it or not, 
whether they’re just stockpiling it, obviously 
yes we would look into that further, but 
if you’ve got a fit 60-year-old that’s still 
working [laughs] they don’t want to come in 
to discuss their medication … amitriptyline, 
we might want to discuss … depends on the 
drugs that they’re on.’ (GP1, F)
Due to high workload pressures and 
time constraints, interviewees reported that 
most medication reviews were conducted 
remotely, without involving the patient. 
Several GPs and pharmacists described 
the medication reviews as a ‘tick box’ 
exercise, which they did in the quickest 
way possible without involving the patient. 
Two GPs and most pharmacists argued 
that a ‘proper’ medication review required 
patient involvement and could not be done 
remotely: 
‘I just do it in the quickest way possible to 
say that I’ve done it … I think quite often we 
don’t involve the patient in the decision and 
part of that is because it is a hell of a lot 
quicker to just tell them to do it.’ (GP1, F) 
GPs who had good continuity of care with 
their patients argued that they applied their 
personal knowledge of patients, and their 
wishes, to the review: 
‘… it isn’t a big practice and so there 
aren’t many people who I don’t know 
particularly when they’re on that many sort 
of medications … I know him … and I know 
his wife and his daughter … so I sort of 
know that actually that’s ticking along fine 
… well there’s quite a lot of foundation of 
knowledge which goes into the medication 
review.’ (GP8, M) 
Involving patients in decisions to stop 
medicines. Most interviewees thought 
patients should be involved in decisions to 
stop their medicines. They argued that some 
patients were happy to accept the possible 
harms of certain medicines because they 
improved their quality of life, and others 
preferred to continue certain medicines 
despite there being little evidence of benefit:
‘… it’s a quality of life decision and 
incontinence is a horrible symptom, it’s 
not going to kill anyone probably but it 
ruins people’s life … my job is to reduce 
suffering not necessarily to make people 
live that much longer … they’d rather take 
something that might do them some harm 
but it means they can tolerate their lives 
more.’ (GP7, F) 
‘… in fact I’ve had it where they remained 
on statins … they wanted to take that and 
continue with it … The cholesterol was quite 
low anyhow so I put it to her that as we get 
older it wasn’t — the evidence isn’t there for 
elderly patients and we have to weigh up 
risks and benefits and she was quite happy 
to stop the statin … So yes I have had both 
ways.’ (P6, F)
DISCUSSION
Summary 
The authors found that GPs typically carried 
out medication reviews outside of the 
patient consultation or during 10-minute 
consultations alongside other problems. 
For some GPs, medication reviews were 
done ‘in the quickest way possible to say 
that it was done’, reflecting time constraints 
and competing priorities. Few of the 
practice-based pharmacists were routinely 
involved in medication reviews. There was 
a perception from GPs and pharmacists 
that pharmacists required protected time to 
undertake a medication review, and, though 
they were generally perceived to be more 
thorough than GPs, they were also felt to be 
less time efficient and had other competing 
priorities. GPs and pharmacists perceived 
a trade-off between involving the patient 
in decisions about their medicines and 
being time efficient, and this emerged as 
an important barrier to stopping medicines. 
Decisions to stop medicines were said to 
be patient dependent, with some patients 
preferring to accept the risk of harm from 
certain medicines, particularly those that 
improved their quality of life.
Strengths and limitations
Grounding the GP interviews using real 
patients as case studies was a key strength 
of this study, prompting a greater depth 
of discussion and highlighting differences 
between the way in which pharmacists 
and GPs carried out medication reviews. 
For example, the pharmacists tended to be 
more fastidious than GPs about checking 
and altering drug doses for patients with 
abnormal kidney blood tests. A further 
strength was that a range of views was 
captured, including those of practice-
based pharmacists, CCG pharmacists, 
and community pharmacists. The iterative 
approach to the study design, whereby the 
topic guide was altered as new themes 
emerged from the data was also a strength. 
One limitation was that interviewees were 
recruited from practices involved in a 
trial; practices, the GPs, and pharmacists 
who take part in clinical trials may not be 
representative of all practices. For logistical 
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reasons some interviews were conducted 
over the phone and the absence of non-
verbal communication for these interviews 
is a limitation. It was outside the scope of this 
study to interview other health professionals 
involved in medication reviews, such as 
nurses, and to interview patients about their 
experiences of medication review. 
Comparison with existing literature
A key finding of this study was that GPs and 
pharmacists recognised the importance of 
involving patients in medication reviews but, 
in practice, due to current high workload 
pressures, most medication reviews were 
conducted outside the consultation with 
no patient involvement, or hastily alongside 
several other problems with little patient 
involvement. This aligns with Hollnagel’s 
idea of the ‘efficiency and thoroughness 
trade-off’ (ETTO) where, within the 
constraints of a high volume of work, it 
is not possible to be both efficient and 
thorough, and practitioners must trade one 
off against the other.21
GPs and pharmacists tended to 
categorise medication reviews as: being 
simple, for example, for younger patients 
prescribed a small number of medicines; 
or complex, for example, for frailer older 
patients with multimorbidity, polypharmacy, 
and(or) memory problems; arguing that 
simple reviews could be carried out quickly 
without involving the patient, but more 
complex reviews required more time and 
patient involvement. This is a pragmatic 
approach, which acknowledges that, due 
to current high demand, it is not possible 
to involve all patients in medication reviews, 
and prioritises those who are most likely 
to benefit — aligning with current NICE 
guidance.15 
GPs and pharmacists appear to be 
making the assumption, however, that 
patients who were prescribed fewer 
medicines with fewer long-term conditions 
would benefit less from a discussion about 
their medicines. 
Remote medication reviews can only 
assess adherence based on how often 
medicines are prescribed, but patients 
and community pharmacists may be 
requesting regular prescriptions that 
are not being dispensed or taken, which 
can lead to considerable medicine waste 
and associated poorer outcomes for the 
patient.22,23 Direct contact between the 
patient and the reviewer also offers the 
opportunity to elucidate experiences of 
adverse events and determine if the patient 
is amenable to suggested changes.24 
Though interviewees preferred to involve 
patients with more complex problems in a 
medication review, this tended to be done 
in the quickest way possible, often during a 
routine consultation alongside several other 
problems, so the extent of shared decision 
making between the patient and doctor is 
questionable. This does not align with NICE 
guidance, which puts a strong emphasis 
on involving patients and their families in 
decisions about their medicines, and on 
reducing medicine waste.15 
Interviewees described several barriers to 
stopping medicines, including perceptions 
that this was not acceptable to some patients, 
a lack of clear guidance, not wanting to tread 
on the toes of hospital colleagues, a need to 
involve patients in decisions that were time 
consuming, and that stopping medicines 
often generated more work. These findings 
align with the results of a systematic review 
that explored prescribers’ perceived barriers 
and enablers to minimise prescribing 
potentially inappropriate medicines.25 As 
in the present study, the review described 
clinician inertia: where health professionals 
are aware of the potential harmful effects 
of certain medicines but, due to high 
workload pressures, choose to ‘turn a blind 
eye’, acknowledging that it was easier to 
continue medicines than to stop them. 
The key barriers to stopping medicines 
included disagreement between the patient 
and clinician about the appropriateness 
of stopping, a fear of withdrawal effects 
or symptom recurrence on stopping 
medicines, and GPs lacking time and 
knowledge to advise patients how to stop 
medicines safely.26 
Implications for research and practice 
Both the pharmacists and GPs described 
the ‘ideal’ scenario of a patient-centred 
medication review, whereby the clinician 
finds out what the patient is actually taking, 
shares concerns, and has an informative 
discussion about the pros and cons of 
continuing or stopping certain higher-risk 
medicines. In line with NICE guidance, 
they argued that frail older patients with 
multimorbidity, polypharmacy, and/or 
cognitive impairment should be prioritised. 
In practice, time constraints prohibited 
health professionals from truly involving 
patients in decisions about their medicines. 
Although a patient-centred model 
of medication review appears to be a 
reasonable approach to reducing harmful 
polypharmacy, there is a lack of evidence 
that medication review, as currently 
practised, or in the ‘ideal’ form described, 
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actually improves clinical outcomes.27 In 
practice, therefore, the pragmatic approach 
taken by practitioners in this study is 
not unreasonable, in that they sought to 
effectively ration the limited time available 
by focusing attention on patients at highest 
risk. 
Further research is required to answer: 
first, which patients would benefit most 
from medication review; second, what are 
the important components of a review; 
third, which mix of health professionals 
should carry out medication reviews; and, 
fourth, whether medication review can 
improve clinical outcomes. 
Further research is planned to triangulate 
the findings of this study by examining 
observational evidence (video consultations) 
of how medication reviews are carried out 
in practice, and the authors are in the initial 
stages of applying for research funding to 
examine such observational evidence.
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